in the pathogenesis of CVD in CKD (8) (9) , due to the effects of uremic toxins (10), proinflammatory cytokines (11), hyperhomocysteinemia (12) , lipid and lipoprotein alterations (13) , endocrinological abnormalities such as insulin resistance (14) , and secondary hyperparathyroidism (15) (16) . All these factors determine in HD patients advanced arterial wall changes characterized both by increased carotid and femoral intima-media thickness (17) (18) , and increased arterial stiffness (19) (20) , which are significant predictors of cardiovascular mortality in healthy populations and in HD patients (5) (6) 21) .
To date, it has still not been established whether atherosclerotic process is accelerated in HD patients, and the studies conducted on the relationship between antioxidant plasma vitamin concentrations (22) (23) (24) (25) (26) , inflammatory markers (26) (27) (28) and carotid atherosclerosis (29) (30) (31) (32) (33) have produced inconclusive results. This case-control study was performed to investigate the relationship between serum antioxidant concentrations, inflammatory markers, and carotid intima-media thickness (CIMT) in healthy subjects and patients undergoing HD with end-stage renal disease (ESRD).
MATERIALS AND METHODS

Subjects
This case control study consisted of 40 non-smoker subjects [20 patients with ESRD treated with maintenance HD (case group), and 20 healthy subjects (control group)]. The case group included patients who had been on maintenance HD for more than three months. This group received three to five hours of hemodialysis, three times a week, 60% of patients received medication for hypertension, 45% for diabetes, and 15% statins for dyslipidemia. No patient was receiving oral or intravenous steroids or non-steroidal anti-inflammatory drugs (NSAIDs). The healthy subjects (control group) were participants of a health check program in the town of Manfredonia.
The exclusion criteria for the healthy control subjects were fasting hyperglycemia as defined by fasting plasma glucose > 120 mg/dL, overt proteinuria, and liver dysfunction as defined by increased serum ALT > 50 IV. Those who were on medication for diabetes mellitus, hypertension, and hyperlipidemia were also excluded.
The participants signed an informed consent before participating in the study, which was performed in accord with the Helsinki Declaration of 1975 as revised in 1983, and approved by the Ethical Review Committee and by the Medical Direction of "San Camillo de Lellis" Hospital, Manfredonia (Foggia, Italy).
Carotid ultrasound investigation
CVI was performed by means of a color-coded ACVSON Sequioia'>" carotid duplex ultrasound machine with a 7.5-MHz linear transducer. The investigation included longitudinal and transverse examinations of the carotid arteries. Both diameter reductions were measured and calculated at the site of maximal stenosis in the extra cranial common carotid arteries (CCA) according to the European Carotid Surgery Trial (ECST) method (34) . The measurements of CIMT were performed at 10 mm proximal to the carotid bulb or 20 mm proximal to the flow divider. CIMT was measured between the leading edge of the first echogenic line (lumen-intima interface) and the second echogenic line (upper layer of the adventitia) in the far (deeper) artery wall. All measurements were performed on frozen, enlarged images (2x) at the end of a heart cycle (end diastole), with the transducer in the mediolateral position (35) . Measurements were performed in both carotid common arteries (CCA), and the larger ofthe 2 values was used in data analysis. Offline analysis of CCA-IMT was made on video images based on the Atherosclerosis Risk in Communities (ARIC) study protocol (36) . Carotid atherosclerosis was defined as a CIMT thickness between 0.8-1.2 mm, while carotid plaque was defined as focal echogenic structures encroaching into the vessel lumen where the CIMT was > 1.2 mm. These cut-offs were chosen because they were used in previous randomized clinical trials (37) .
Clinical and laboratory data
After CUI, demographic characteristics (age, gender), body mass index (BMI), and laboratory data were collected. Venous blood samples were obtained for the measurement of laboratory values. Measurements included: total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, C-reactive protein (CRP), and fibrinogen (measured at Analysis Laboratory of the "San Camillo de Lellis" Hospital, Manfredonia, Foggia, Italy) and plasma concentrations of vitamin A, vitamin E, lycopene and~-carotene (measured at the Department of Clinical Biochemistry, University "G. d' Annunzio" Chieti, Italy). All investigators and laboratory personnel were blinded to the subject's CIMT. Antecubital venous blood samples from all subjects were handled identically and blindly through all stages ofblood collection, storage, retrieval, and analytic processes.
Antioxidant measurements
Blood samples were collected between 8:00 and 10: OOa.m. in polypropylene tubes containing EDTA I mM (in HD patients, blood was taken at least 44 hours after the previous dialysis session) . Samples were stored in an ice box prior to centrifugation at 3000 g for 10 minutes at 4°C. 200 III aliquots of plasma were transferred into foiled-wrapped polypropylene tubes. Plasma samples were either used for extraction immediately or stored in the dark at -80°C until analysis was performed. Sample preparation is as described in Lee et al. (38) .
Vitamin A, vitamin E, Iycopene, and~-carotene were determined by HPLC. Two Water Pumps SIS HPLC equipped with Waters auto injector (model 717 plus auto sampler) and Waters 996 photodiode array (PDA) detector were used as HPLC system. Data acquisition and processing were performed using a chromatography software, Empower-Pro, by Waters. Analysis was performed by isocratic elution. The flow rate was 1.5 ml/min. The mobile phases used were: A-methanol!nbutanol! water (89.5 /5/5.5 v/v/v) premixed and vacuumfiltered through a 0.45 11m polypropylene membrane filter (Whatman) before use, and B-methanol!n-butanol/water (76/19 .5/4.5 v/v/v) premixed and vacuum filtered before use as for A. The gradient elution profile was as follows: 0-7 min 100% A; 7-15 min 100% B; 15-20 min 100% A for column riequilibration. Auto injections of 20 III were performed at 5°C. The analytical column used was a replaceable Partisphere 5 C-18 cartridge (110 x 4.7 mm inner diameter, 5 11m particle size ; Whatman) protected by a guard cartridge (C-18, 5 11m) system and maintained at 45°C. PDA wavelength range was from 270 nm to 460 nm and the chromatograms were extracted at 340 nm for Vitamin A, 288 nm for Vitamin E and Vitamin E-Acetate (used as internal standard), 441 nm for Iycopene and~ carotene. The run time was 20 min.
Statistical analysis
The results are presented as mean ± standard deviation (SD). The difference between two groups was assessed by analysis of variance (ANOVA). The statistical significance of differences was examined using Student t-test (continuous variables) and X 2 test (categorical variables). A two-sided p value <0.05 was considered statistically significant. Data were analyzed using SPSS statistical software (version 15.0 for Windows; SPSS Inc., Chicago).
RESULTS
The various demographic characteristics are summarized in Table I . The inflammatory markers, plasma lipids, and antioxidant vitamins/carotenoids are summarized in Table II. CIMT correlate negatively with antioxidant lower concentrations of vitamin A, vitamin E, lycopene , and~-carotene (p<O.OO I) and positively with high concentrations of serum inflammatory markers (CRP, and fibrinogen) (p<O.OOI) (Table II) . Fig. I shows the CIMT of the two groups. The case group had a significantly greater CIMT (1.95 ± 0.82 mm left; 2.23 ± 0.64 mm right) than the healthy control subjects (0.66 ± 0.22 mm left; 0.71 ± 0.18 mm right) (p< 0.001).
DISCUSSION
The primary findings of our study show that low plasma levels of antioxidant vitamins (A, E) and carotenoids (lycopene and p-carotene) are associated with carotid atherosclerosis in patients with ESRD. In our study, in fact, elevated CIMT was significantly associated with having a low concentration of all antioxidants measured (vitamin A, vitamin E, lycopene and p-carotene) and a higher concentration of inflammatory factors, including CRP and fibrinogen.
Two case-control studies with opposite results have investigated the association between plasma vitamin A concentration and ESRD. Zima et al. (22) found that vitamin A (retinol) concentration was significantly higher in hemodialysis (HD) patients compared to healthy controls, while Lim et al. (23) found that the plasma level of retinol in HD patients were lower than those of controls. The last study suggested that the plasma ·levels of retinol were altered in ESRD and may be considered as markers of oxidative stress in HD patients.
Even for vitamin E, the results of published studies are conflicting. Many studies have shown no different vitamin E (a-tocopherol) plasma concentration in HD patients with ESRD in respect to control groups (22, (24) (25) . On the contrary, Lim et al. (23) found that the plasma levels of 0-and ytocopherol were lower in HD patients in respect to controls. Besides, Usberti et al. (26) examined the relationship between the severity of CVD (index as the result of variably combined cardiac, cerebral, and vascular pathologies) and some markers of oxidative stress and antioxidant activity in HD patients. They found that CVD were inversely correlated with atocopherol plasma concentration.
Two studies have investigated the relationship with lycopene, p-carotene and ESRD. In these studies, the plasma concentrations of lycopene and p-carotene were significantly lower in the HD patients than in the healthy volunteers (23) (24) .
Regarding the relation between CIMT and plasma antioxidant/inflammatory marker concentrations, Brzosko et al. (29) investigated in HD the traditional and potential risk factors for the development of CVD and variation in CIMT. They found a higher mean CIMT and serum fibrinogen in HD patients compared to the control group, reflecting a high risk for ischemic heart disease in HD patients. Even in the Atherosclerosis and Folic Acid Supplementation (AFAS) Trial, a prospective observational study including 315 patients with several stages of chronic kidney disease (CKD), Zoungas et al. (30) found that common indices of arterial structure (CIMT) and stiffuess (aorto-femoral pulse wave velocity, and systemic arterial compliance) were predictive of all cardiovascular events. Some published studies found a significant positive correlation between CIMT and duration of HD (31, (39) (40) (41) , whereas others did not (17, (42) (43) .
Finally, plasma inflammation markers, such as CRP and fibrinogen, are elevated in predialysis and HD patients (44) . In particular, CRP represent an important risk factor for endothelial dysfunction and mortality in the ESRD population, not significantly modified by administration/supplementation of antioxidant substances (45) . Fibrinogen is elevated in HD patients, influences arterial remodelling, and correlates positively with CIMT (29) . Higher concentrations of these substances may be involved in the atherogenic inflammatory process in predialysis and HD patients (46) (47) .
Atherosclerosis represent an advanced process in patients with ESRD. Our study demonstrates that these patients have a significantly increased CIMT, independent of age or gender, which correlated with high plasma concentration of inflammatory markers (CRP, fibrinogen) and plasma lower concentration of antioxidant substances (vitamin A, vitamin E, lycopene and p-carotene). These results support the inflammatory pathophysiology characteristic of atherosclerosis, and suggest that ESRD and/or metabolic alterations secondary to renal failure promote atherosclerotic process with consequent vascular damage (48) (49) . This is the principal reason responsible for the increased risk of atherosclerosis in patients with chronic renal failure, a multifactorial disease which involves several metabolic and structural arterial changes that characterize the accelerated atherosclerotic process in patients whose renal function is reduced.
Our study has some limitations. Firstly, the patients were studied while under medication for hypertension, dyslipidemia, and other metabolic abnormalities associated with chronic renal failure, and for this reason our data might have partially underestimated the effects of these factors on CIMT. Secondly, in our study we did not evaluate the effects ofother factors (parathyroid hormone, homocysteine, calcium-phosphorus metabolism) which might have added to the results of the analyses. Further larger studies on predialysis and HD patients are needed to elucidate the precise mechanism by which renal failure promotes atherosclerosis.
